PRESCRIPTION DRUG MONITORING PROGRAM TRAINING AND TECHNICAL ASSISTANCE CENTER
The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) at the Institute for Intergovernmental Research (IIR) provides a comprehensive array of services, support, resources, & strategies to PDMPs, federal partners and other stakeholders to further the efforts and effectiveness of PDMPs in combating the misuse and diversion of prescription drugs.
News & Events
-
Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV
Read More November 12, 2026On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N -[(2 S, 3 R)-2-[[3-(3,5-difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA. This rule is effective November 12, 2026
-
Aggregate Production Quota (APQ) Adjustments
Read More November 10, 2026November 10, 2026 Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination, DEA has considered the factors set forth in 21 CFR 1303.13(b) (opens in a new tab) in accordance with 21 U.S.C. 826(a) (opens in a new tab) and is expediting publication of this determination to comply with the timeframes specified in 21 U.S.C. 826(h)(1) (opens in a new tab). This final order is effective November 10, 2026.
November 10, 2026 Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. Interested persons may file written comments on this notice in accordance with 21 CFR 1303.11(c) (opens in a new tab) and 1315.11(d) (opens in a new tab). Electronic comments must be submitted, and written comments must be postmarked, on or before December 10, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised.
-
CMS Agency Information Collection Activities: Proposed Collection; Comment Request
Read More November 05, 2026The following comment period, while not directly effecting Prescription Drug Monitoring Programs (PDMPs), may have an indirect impact with the reporing by other entities and may be worth monitoring by PDMPs and stakeholders.
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
For additional information, see the following link: Federal Register :: Agency Information Collection Activities: Proposed Collection; Comment Request (opens in a new tab)
Our focus is to improve consistency among PDMPs, facilitate coordination between PDMPs and state and national stakeholders, increase PDMP efficiencies, measure performance and effectiveness, and promote best practices.
REQUEST PDMP TTA
Combat prescription misuse with RxCheck! Facilitate seamless data sharing among states, integrate with EHR systems, and join the nationwide PDMP movement. Developed with BJA support, RxCheck ensures secure data governance, empowering states to own and control their information.
LEARN MORE
